ECRAID-Base Launches European Clinical Research Alliance

Read more
Current status: Ongoing


HOspital NEtwork STudy – Preparation for a Randomized Evaluation of anti-Pneumonia Strategies (HONEST-PREPS) is a prospective, observational, multicenter cohort study. The study population are the patients admitted to an intensive care unit (ICU) at risk for hospital acquired and ventilator associated pneumonia (HAP/VAP).

The aim of the HONEST-PREPS is to set up an infrastructure to prospectively enroll patients at risks of HAP/VAP in the ICU. Collected data will be used to inform future diagnostic, preventative and therapeutic trials. In addition to capturing HAP/VAP episodes in a timely manner, HONEST-PREPS will determine the incidence, microbiological etiology (including antibiotic resistance), management and outcome of HAP/VAP in the ICU.

Study status: Preparation phase (2019 May – March 2020), Trial period (March 2020 – ongoing)

Country level information:

  • Serbia: 3 sites recruiting, 1 site in start-up process
  • Czech Republic: 2 sites recruiting, 2 sites initiated and pending activation
  • Croatia: 1 site recruiting and 2 sites in start-up process
  • Romania: 1 site recruiting
  • Hungary: 1 site in start-up process
  • Latvia: 2 sites in start-up process
  • Albania: 1 site in start-up process

Planned study duration

HONEST-PREPS observational study is a preparation for a subsequent platform trial (HONEST-PLATFORM: HOspital NEtwork STudy – PLAtform Trial FOR antibacterial Molecules). The set-up of the infrastructure, training of clinical staff and laboratory staff, data collection and preparation for the HONEST-PLATFORM is expected to take 18-24 months.


Rapid Evolution and Host Immunity Drive the Rise and Fall of Antibiotic Resistance During Acute Infection

Antibiotic resistance poses a serious threat to human health. Resistant infections now cause more than 750,000 deaths per year and are predicted to in...


SAATELLITE Results Published in Lancet Infectious Diseases

The SAATELLITE study team is thrilled to announce the manuscript entitled “Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus...